Amgen posts results of Phase 3b long-term extension study of apremilast in pediatric psoriasis
The study, enrolling 160 participants, was terminated after a primary completion date of October 30, 2025. It evaluated up to 208 weeks of open-label apremilast therapy followed by an 8-week observational follow-up.
Primary source
ClinicalTrials.gov results record, November 20, 2026
A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
Read the source: A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation